Halozyme Therapeutics (NASDAQ:HALO) Director Bernadette Connaughton Sells 1,626 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Wednesday, July 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $76.71, for a total value of $124,653.75.
• On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $66.21, for a total value of $107,591.25.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $102.62 on Wednesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $104.78. The firm’s 50-day simple moving average is $77.89 and its 200 day simple moving average is $71.92. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock has a market cap of $11.65 billion, a P/E ratio of 30.63, a P/E/G ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HALO shares. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Citizens Jmp lifted their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Finally, TD Cowen raised their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.20.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC lifted its stake in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. MidFirst Bank purchased a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $28,000. Finally, Harbour Investments Inc. lifted its position in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.